P/E ratio for Moderna (MRNA)
P/E ratio as of April 2025 (TTM): -2.80
According to Moderna 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.80416. At the end of 2022 the company had a P/E ratio of 8.50.
P/E ratio history for Moderna from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 8.50 | 1.4% |
| 2021 | 8.39 | -115.58% |
| 2020 | -53.9 | 326.73% |
| 2019 | -12.6 | -6.53% |
| 2018 | -13.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -1.01 | -63.92% | 🇺🇸 USA |
 | 44.7 | -1,692.51% | 🇺🇸 USA |
 | -0.0045 | -99.84% | 🇺🇸 USA |
 | -59.9 | 2,036.47% | 🇺🇸 USA |
 | 28.6 | -1,119.11% | 🇨🇭 Switzerland |
 | -6.44 | 129.49% | 🇺🇸 USA |
 | 11.0 | -492.00% | 🇺🇸 USA |
 | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.